Showing 3091-3100 of 5771 results for "".
- iOR Partners Co-Founder and Chairman of the Board, Daniel S. Durrie, MD, Retireshttps://modernod.com/news/ior-partners-co-founder-and-chairman-of-the-board-daniel-s-durrie-md-retires/2482267/iOR Partners announced the retirement of Daniel S. Durrie, MD, as Chairman of the Board of Directors. Dr. Durrie co-founded iOR Partners, a provider of ophthalmic office-based surgery (OBS), in 2018. iOR's model provides surgeons with turnkey OBS suites and support service
- EyePoint Fails to Reach Primary Efficacy Endpoint in Phase 2 Trial of Duravyu in NPDRhttps://modernod.com/news/eyepoint-fails-to-reach-primary-efficacy-endpoint-in-phase-2-trial-of-duravyu-in-npdr/2482265/EyePoint Pharmaceuticals announced topline results of its phase 2 PAVIA clinical trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). In the trial, Duravyu did not meet the pre-specified p
- Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at ARVOhttps://modernod.com/news/vesigen-to-present-new-preclinical-data-on-ophthalmology-applications-of-engineered-armms-at-arvo/2482262/Vesigen Therapeutics announced that the company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle, from May 5-9. Vesigen’s techno
- Johnson & Johnson to Debut EYE-RD Global Registry at ARVOhttps://modernod.com/news/johnson-johnson-to-debut-eye-rd-global-registry-at-arvo/2482261/Johnson & Johnson announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The company's two oral presentations wil
- Lumibird Launches C.DIAG Dry Eye Diagnostic Aid Platformhttps://modernod.com/news/lumibird-launches-cdiag-dry-eye-diagnostic-aid-platform-platform/2482260/Lumibird Medical announced the launch of the C.DIAG, a new-generation dry eye diagnostic aid platform with integrated AI algorithms. This new component of the C.SUITE is designed to enable healthcare professionals to diagnose, treat and educate dry eye patients. &ldq
- FDA Accepts Eluminex Biosciences' IND Application for Trispecific Fusion Antibody for DMEhttps://modernod.com/news/fda-accepts-eluminex-biosciences-ind-application-for-trispecific-fusion-antibody-for-dme/2482259/Eluminex Biosciences announced the acceptance of its EB-105 IND application to the FDA. EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the treatment of DM
- Safilo North America Appoints New Leaderhttps://modernod.com/news/safilo-north-america-appoints-new-leader/2482258/Safilo North America announced the appointment of Gabriele Cusani Sodano as president and chief commercial officer, effective April 2024. The company says Mr. Cusani brings a wealth of experience and a proven track record to succeed in this new role, which will focus on accelerating the implement
- Qlaris Bio Completes $24 Million Series B Financing Round to Advance IOP-lowering Drug Candidate for Glaucomahttps://modernod.com/news/qlaris-bio-completes-24-million-series-b-financing-round-to-advance-iop-lowering-drug-candidate-for-glaucoma/2482252/Qlaris Bio announced it has closed a $24 million Series B financing round to support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower IOP by targeting episcleral venous pressure (EVP). Qlaris is currently conducting two US ph
- RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Wet AMD Treatmenthttps://modernod.com/news/revopsis-secures-165-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-wet-amd-treatment/2482246/RevOpsis Therapeutics announced it has successfully closed its first seed funding round, raising $16.5 million to develop and commercialize treatments for chronic multifactorial diseases through the company's fully human multispecific proprietary Rev-Mod Platform. The 
- World Council of Optometry and CooperVision Partner on Myopia Management Navigator Educational Resourcehttps://modernod.com/news/world-council-of-optometry-and-coopervision-partneron-myopia-management-navigator-educational-resource/2482245/With the goal of advancing myopia management as a standard of care, the World Council of Optometry (WCO) announced a partnership with CooperVision to introduce an interactive and educational resource for ey